UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Commission file number 0-27078 HENRY SCHEIN, INC. (Exact name of registrant as specified in its charter) Delaware 11-3136595 incorporation or organization) (State or other jurisdiction of (I.R.S. Employer Identification No.) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.01 per share HSIC The Nasdaq ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-K (MARK ONE) Commission File No. 000-11676 _____________________ BEL FUSE INC. (Exact name of registrant as specified in its charter) New Jersey 22-1463699 (State of incorporation) (I.R.S. Employer Identification No.) 300 Executive Drive, Suite 300 West Orange, NJ 07052 (Address of principal executive offices and zip code) Registrant's telephone number, including area code: (201) 432-0463 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-K (MARK ONE) Commission File No. 000-11676 _____________________ BEL FUSE INC. (Exact name of registrant as specified in its charter) New Jersey 22-1463699 (State of incorporation) (I.R.S. Employer Identification No.) 300 Executive Drive, Suite 300 West Orange, NJ 07052 (Address of principal executive offices and zip code) Registrant's telephone number, including area code: (201) 432-0463 ...

Exhibit 99.1 GLOBAL INDUSTRIAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS Fourth Quarter Sales Increased 14.3%; Operating Income Improved 35.2%; EPS Grew 40.7% Full Year Sales of $1.38 Billion, Increased 4.8%; Operating Income Improved 21.2% Quarterly Dividend Increased by 7.7% to $0.28 PORT WASHINGTON, NY, February 24, 2026 – Global Industrial Company (NYSE: GIC), a value-added distributor and source for industrial equipment and supplies, today announced financial results for the fourth qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ | | | O ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38492 Kiniksa Pharmaceuticals International, plc (Exact name of registrant as specified in its charter) England an ...

Financial Performance - UFP Technologies reported 2025 net income of $68.3 million, a 15.8% increase from $59.0 million in 2024[2] - Net sales for 2025 reached $602.8 million, up 19.5% from $504.4 million in 2024, driven by a 23.2% increase in medical sales[4] - Adjusted net income for 2025 grew 12.7% to $76.1 million from $67.6 million in 2024[5] - Operating income for 2025 increased 14.1% to $92.3 million, despite $6.3 million in labor-related inefficiencies[4] - Fourth quarter sales increased 3.4% to $148.9 million compared to $144.1 million in Q4 2024[5] - Adjusted operating income for the year ended December 31, 2025, was $102.874 million, up from $92.302 million in 2024[26] - Adjusted net income for the three months ended December 31, 2025, was $19.034 million, compared to $19.163 million for the same period in 2024[28] - Adjusted EBITDA for 2025 increased to $121.1 million from $107.3 million in 2024[6] - Adjusted EBITDA for the year ended December 31, 2025, was $121.100 million, compared to $107.321 million in 2024[30] Cost and Margin Analysis - Gross margin for 2025 decreased to 28.3% from 29.1% in 2024, impacted by labor costs at the AJR facility[5] - SG&A expenses for 2025 rose 24.5% to $77.4 million, with SG&A as a percentage of sales increasing to 12.8%[5] - Adjusted gross margin for the three months ended December 31, 2025, was 28.2%, compared to 29.2% for the same period in 2024[22] Acquisitions and Expansion - The company completed four acquisitions in 2024 and three in 2025, with integrations progressing well[4] - UFP Technologies plans to expand operations in the Dominican Republic, including new facilities and contract extensions[4] - The company is focused on identifying suitable acquisition candidates and integrating them effectively[16] Future Outlook - The company expects an increase in revenue due to new robotic programs and facility expansions[16] - The company anticipates improved profitability at its Illinois facility and successful program transfers to the Dominican Republic[16] Risks and Challenges - Risks include customer concentration, potential delays in production, and challenges in executing business plans[16] - Organic sales growth rate for the year ended December 31, 2025, was 1.5%, while the three months ended December 31, 2025, showed a decline of 0.03%[20]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39781 _____________________________ AbCellera Biologics Inc. (Exact name of Registrant as specified in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35370 Luxfer Holdings PLC (Exact Name of Registrant as Specified in Its Charter) England and Wales 98-1024030 State or Other Jurisdiction of Incorporation or Organization WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 I.R.S. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________ FORM 10-K ______________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ______ ...